Real-world Effectiveness and Safety of Pharmacological Thromboprophylaxis in Patients Undergoing Primary Total Hip and Knee Arthroplasty: A Narrative Review

Overview

Journal J Orthop

Specialty Orthopedics

Date 2020 Feb 7

PMID 32025127

Citations 1

Authors

Astrid Blicher Schelde

Astrid Eliasen

Jonas Bjerring Olesen

Thomas Bo Jensen

Espen Jimenez-Solem

Affiliations

Soon will be listed here.

Abstract

In this narrative review of the real-world effectiveness and safety of pharmacological thromboprophylaxis following primary total hip and knee arthroplasty, a total of 12 non-interventional observational studies were included. Pharmacological thromboprophylaxis included warfarin, heparins, dabigatran, rivaroxaban, apixaban, acetylsalicylic acid, and fondaparinux. The absolute risks varied across the included studies. These variations can be explained by differences in patient populations, drug exposure, follow-up time, and definition of outcomes, which makes it a challenge to compare the risk estimates. These findings emphasize the need for a large population-based real-world study to provide comparable risk estimates associated with different pharmacological thromboprophylaxis.

Citing Articles

Post-operative oral chemoprophylaxis in patients undergoing hip arthroscopy mitigates VTE risk with a low side-effect profile.

Verhoogt W, Pietrzak J, Ayeni O, Cakic J J Hip Preserv Surg. 2021; 7(3):524-532.

PMID: 33948208 PMC: 8081424. DOI: 10.1093/jhps/hnaa063.

References

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

Falck-Ytter Y, Francis C, Johanson N, Curley C, Dahl O, Schulman S . Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-e325S. PMC: 3278063. DOI: 10.1378/chest.11-2404. View

Jiang L, Zhang S, Zhao Y . Stacked Modalities' Thromboprophylactic Therapy for Patients Undergoing Total Knee Replacement Surgery. J Knee Surg. 2016; 30(3):218-222. DOI: 10.1055/s-0036-1584188. View

Bloch B, Patel V, Best A . Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J. 2014; 96-B(1):122-6. DOI: 10.1302/0301-620X.96B1.31569. View

Bayley E, Brown S, Bhamber N, Howard P . Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study. Bone Joint J. 2016; 98-B(5):585-8. DOI: 10.1302/0301-620X.98B5.34996. View

King D, Pow R, Dickison D, Vale P . Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. Intern Med J. 2016; 46(9):1030-7. DOI: 10.1111/imj.13139. View

Sachs R, Smith J, Kuney M, Paxton L . Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty. 2003; 18(4):389-95. DOI: 10.1016/s0883-5403(03)00071-8. View

Parry M, Wylde V, Blom A . Ninety-day mortality after elective total hip replacement: 1549 patients using aspirin as a thromboprophylactic agent. J Bone Joint Surg Br. 2008; 90(3):306-7. DOI: 10.1302/0301-620X.90B3.19935. View

Borgen P, Dahl O, Reikeras O . Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int. 2010; 20(3):301-7. DOI: 10.1177/112070001002000302. View

10.

Zuidgeest M, Goetz I, Groenwold R, Irving E, van Thiel G, Grobbee D . Series: Pragmatic trials and real world evidence: Paper 1. Introduction. J Clin Epidemiol. 2017; 88:7-13. DOI: 10.1016/j.jclinepi.2016.12.023. View

11.

Izumi M, Migita K, Nakamura M, Jiuchi Y, Sakai T, Yamaguchi T . Risk of venous thromboembolism after total knee arthroplasty in patients with rheumatoid arthritis. J Rheumatol. 2015; 42(6):928-34. DOI: 10.3899/jrheum.140768. View

12.

Goel R, Fleischman A, Tan T, Sterbis E, Huang R, Higuera C . Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin warfarin. Bone Joint J. 2018; 100-B(1 Supple A):68-75. PMC: 6424442. DOI: 10.1302/0301-620X.100B1.BJJ-2017-0587.R1. View

13.

Blann A, Lip G . Venous thromboembolism. BMJ. 2006; 332(7535):215-9. PMC: 1352055. DOI: 10.1136/bmj.332.7535.215. View

14.

Westrich G, Farrell C, Bono J, Ranawat C, Salvati E, Sculco T . The incidence of venous thromboembolism after total hip arthroplasty: a specific hypotensive epidural anesthesia protocol. J Arthroplasty. 1999; 14(4):456-63. DOI: 10.1016/s0883-5403(99)90101-8. View

15.

Sogaard K, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen H . 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014; 130(10):829-36. DOI: 10.1161/CIRCULATIONAHA.114.009107. View

16.

Kremers H, Larson D, Crowson C, Kremers W, Washington R, Steiner C . Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015; 97(17):1386-97. PMC: 4551172. DOI: 10.2106/JBJS.N.01141. View

17.

Radzak K, Wages J, Hall K, Nakasone C . Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. J Arthroplasty. 2016; 31(11):2447-2451. DOI: 10.1016/j.arth.2015.10.023. View

18.

Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Bandel T . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-86. DOI: 10.1056/NEJMoa076016. View

19.

Haighton M, Kempen D, Wolterbeek N, Marting L, van Dijk M, Veen R . Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty. J Orthop Surg Res. 2015; 10:145. PMC: 4573310. DOI: 10.1186/s13018-015-0285-6. View